CATAFLAM
LOE ApproachingNDAORALTABLET
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAFLAM is an oral tablet small-molecule NSAID approved by Novartis in 1993. The drug's specific mechanism of action and clinical indications are not fully documented in this dataset. It is a mature product approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams should expect resource optimization and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CATAFLAM offers limited career growth potential as a LOE-approaching asset with no linked job openings. Roles on this product focus on maximizing existing sales, managing margin erosion, and transitioning to post-patent strategies. Career progression is better pursued on growth-stage or newly launched assets within the Novartis portfolio.
Brand ManagerField Sales Representative
Worked on CATAFLAM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.